Logo

Biotheranostics: Matt Sargent

Apr 01, 2020

Biotheranostics has promoted its vice president of sales, Matt Sargent, to the position of chief commercial officer. In his new role, Sargent will be responsible for sales, marketing, market access, and customer service, and will lead the company's growth of its core tests: Breast Cancer Index and CancerTYPE ID. Sargent holds over 17 years of experience in the oncology diagnostic space during which he led the launch of Breast Cancer Index at Biotheranostics and the launch of the oncology division of Caris Life Sciences, where he served as vice president of oncology sales.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.